Telix Pharmaceuticals Limited (TLX) Increases R&D by 47%, Progresses Key Prostate and Brain Cancer Trials

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. Telix Pharmaceuticals Limited is one of them.

Melbourne-based Telix Pharmaceuticals Limited (NASDAQ:TLX) is advancing its global footprint in precision oncology and targeted radiotherapies, with active clinical programs in prostate cancer and rare oncologic conditions.

In its 2025 half-year update, the company reported a 30% revenue increase in its Precision Medicine segment, led by strong demand for its flagship PET imaging agent, Illuccix, and the launch of new products, including Gozellix, Zircaix, and Pixclara, across international markets. Telix Pharmaceuticals Limited (NASDAQ:TLX) has also expanded its manufacturing capabilities through Telix Manufacturing Solutions, supporting clinical and commercial operations worldwide.

Despite being featured among the most oversold stocks in recent months, the corporation continues to invest heavily in its therapeutics pipeline, increasing R&D spending by 47% year-over-year to $81.6 million. Key milestones include completion of target enrollment for the Phase 3 TLX591 trial in advanced metastatic castration-resistant prostate cancer (mCRPC), initiation of a Phase 1 first-in-human trial for TLX592, and the start of the pivotal IPAX BrIGHT trial for TLX101 in metastatic brain cancer. Additionally, the company gained IND approval for a Phase 1 study of TLX090 to manage bone pain in osteoblastic metastatic disease.

Diagnostic growth is further supported by the dosing of the first patient in the pivotal Phase 3 BiPASS trial, aimed at expanding indications for Illuccix and Gozellix in prostate cancer imaging. These developments highlight Telix Pharmaceuticals Limited (NASDAQ:TLX)’s dual strategy of commercial expansion and clinical innovation, positioning the company as a leader in radiopharmaceuticals and precision oncology globally.

While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.